NCT03645096View on ClinicalTrials.gov

Development of Pregnenolone as a Treatment for Depression

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions
Major Depressive Disorder
Interventions
DRUG

Pregnenolone 500 mg

Pregnenolone 500 mg capsule.

DRUG

Pregnenolone 800 mg

Pregnenolone 800 mg capsule.

DRUG

Placebo

Placebo capsule manufactured to mimic pregnenolone capsule.

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

University of Texas Southwestern Medical Center

OTHER

NCT03645096 - Development of Pregnenolone as a Treatment for Depression | Biotech Hunter | Biotech Hunter